The effects of 4 weeks' administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial. Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 ~tg four times per day (breakfast, lunch, dinner, and evening snack), 30 ~tg three times per day (breakfast, lunch and dinner [BLD]), 30 ~tg three times per day (breakfast, dinner and evening snack [BDS]), and 60 ~tg twice per day (breakfast and dinner). After 4 weeks of pramlintide 30 ~tg four times per day administration, there was a statistically significant reduction in the mean 24 h plasma glucose concentration when compared to placebo (-1.4 + 0.5 vs 0.3 + 0.5 ~tmol/1, p = 0.009). Serum fructosamine concentrations were reduced 62 + 10 ~tmol/l in the pramlintide 30 mg four times per day group, 43 + 7 ~tmol/1 in the pramlintide 30 ~tg three times per day (BLD) group, 47 + 6 ~tmol/1 in the pramlintide 30 ~tg three times per day (BDS) group, 46 + 7 ~tmol/1 in the pramlintide 60~tg twice per day group, and 29 + 8 pmol/l by placebo. The incidence of hypoglycaemia was not different in any pramlintide group compared to the placebo group. Nausea, the most frequent adverse event, subsided after the first week of treatment in the majority of patients. In conclusion, pramlintide improved blood glucose control over a 4-week period without increased hypoglycaemia and was well tolerated. Future studies using a longer period of pramlintide administration with assessment of HbAlc as the measurement of glycaemic control are warranted. [Diabetologia (1997[Diabetologia ( ) 40: 1278[Diabetologia ( -1285 Keywonis Pramlintide, amylin, serum fructosamine, plasma glucose, HbAlc, IDDM.
curve; Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; NS, not statistically significant; NAP, not applicable; BLD, breakfast, lunch and dinner; BDS, breakfast, dinner and evening snack; HbAlc, hemoglobin Ale. glucose concentration. In normal human subjects, fasting concentrations of amylin range from 4 to 11 pmol/1 and increase twofold to threefold following a meal or during an oral glucose tolerance test [2, 3] . In patients with insulin-dependent diabetes (IDDM), basal amylin concentrations are either undetectable or at the lower end of the detectable range and do not increase in response to a glucose load [4] . Amylin has been shown to have a number of biologic actions including suppression of glucagon secretion [5] and modulation of gastric emptying in dogs and rats, thereby reducing postprandial plasma glucose concentrations [6, 7] . A similar peptide, called IAP and, subsequently islet amyloid polypeptide (IAPP) by Westermark et al. [8] was isolated from human insulinomas (islet cell tumours) but not completely purified or chemically characterized. Based presumably on later genetic work, some authors have subsequently referred to amylin as either "amylin" or "lAPP".
Pramlintide is a non-naturally occurring analogue of amylin that incorporates proline amino acids at positions 25, 28 and 29 of the human amylin molecule and is substantially different from and better than human amylin. In the example, it is soluble in aqueous solution and does not self-aggregate. Recent studies in patients with IDDM have demonstrated significant reductions in postprandial glucose concentrations following intravenous infusion of pramlintide [9] or 14 days of subcutaneous administration of pramlintide [10] . The intravenous infusion of pramlintide decreased postprandial plasma glucose concentrations in patients with IDDM after a Sustacal meal challenge, but not after an intravenous glucose load [9] . These results support the idea that one mechanism of action of pramlintide is to restrain gastric emptying resulting in slowed glucose absorption. This slowed glucose absorption in turn leads to a decrease in the unwanted rises in the postprandial glucose that are usually observed in people with IDDM. The present study was designed as a double-blind, randomized~'placebo-controlled, parallel-group trial to examine the effects of 4 weeks of subcutaneous pramlintide administration on markers of blood glucose control in patients with IDDM. Four pramlintide dosing regimens were compared to placebo for their effects on 24-h plasma glucose profiles and changes in serum fructosamine concentrations, as well as for safety and tolerability.
self-administered four injections of study drug daily at a site separate from their insulin injections within 15 min of each meal and the evening snack. Patients were provided with four vials to be used each day, each vial was designated for a specific injection time. During the double-blind period, patients randomized to the BID or TID pramlintide regimen administered placebo before the meals in which they were not to receive pramlintide. Pramlintide or placebo was administered into the subcutaneous tissue of the anterior abdominal wall.
Patients were instructed to remain on their usual diets, insulin and exercise regimens throughout the study, unless otherwise instructed by the investigator, and to abstain from alcoholic beverages prior to all clinic visits. Each patient monitored and kept a diary of preprandial and bedtime blood glucose concentrations, daily insulin doses, hypoglycaemic signs and symptoms and dietary supplements (snacks) throughout the trial. There were six clinic visits including the screening visit. At each clinic visit, the investigator determined whether any adverse events had occurred and recorded this information.
Placebo lead-in period.
On the first day of the placebo lead-in period (Study Day 1), patients returned to the clinic for evaluation and were instructed in study drug administration, diary card completion and the use of a glucose meter. Patients then began 8 days of single-blind placebo QID administration.
On Study Day 8, the patients reported to the clinic after fasting since the prior evening for their first 24-h plasma glucose profile. During the profile, patients administered their usual doses of insulin 30 min before meals. Placebo was administered 15 min prior to each meal and the evening snack. Glucose samples collected during the 24-h glucose profile were used to calculate the 24 h glucose area under the curve (AUC), 24-h mean glucose concentration (calculated as glucose AUC/time of collection period for AUC), 24'-h maximum glucose concentration (Cmax) and 24-h minimum glucose concentration (Cmin). The results of this 24-h evaluation period served as the baseline assessment for study drug evaluation.
Subjects and methods
Patients. Participants were males and females 18 to 66 years of age with a history of IDDM from 2 months to 43 years. At entry the patients had HbAlc levels of 6.9 to 13.1% (normal reference range for assay = 4.30-6.10 %), a basal C-peptide concentration less than 1.0 ng/ml and/or a history of diabetic ketoacidosis, and negative results for serum hepatitis B surface antigen (HbsAg).
Study procedures. An institutional review board approved all procedures. At the screening visit a signed consent form was obtained, a physical examination was completed, and blood chemistry, haematology and urinalysis were performed. Blood samples were also tested for serum fructosamine concentrations and HbAlc levels. Patients who satisfied the inclusion criteria and met the screening requirements returned to the clinic within 21 days to begin the 8-day, single-blind placebo lead-in period. Following the placebo lead-in period, patients were randomized to receive placebo or one of four dose regimens of pramlintide: 30 vg four times per day (QID), before breakfast, lunch, dinner and evening snack; 30 ~tg three times per day (TID), before breakfast, lunch and dinner (BLD); 30 ~tg three times per day (TID) before breakfast, dinner and evening snack (BDS); or 60 Ixg twice per day (BID), before breakfast and dinner. Throughout the study drug period, patients Study drug period. On Study Day 9 patients were randomized, had an abbreviated physical examination, were discharged from the clinic, and began 28 days of double-blind study drug administration. On Study Days 15 and 22, patients retumed to the clinic for an interim history and abbreviated physical examination. Routine safety laboratories also were drawn on Study Day 15.
The final 24-h plasma glucose profile was performed on Study Day 36. Samples for routine laboratory tests and serum fructosamine measurements were collected at the first time point of the profile. Samples for plasma glucose measurements were obtained at the same time points as Study Day 8. After completion of the 24-h plasma glucose profile on Study Day 37, patients were discontinued from study drug, had a physical examination and interim history. They were then discharged from the clinic when stable in the opinion of the investigator.
Measurements
Plasma glucose. Blood samples were immediately centrifuged and the plasma was separated, transferred to a clean tube and stored frozen until analysis. Plasma glucose concentrations were measured by Endocrine Sciences (Calabasas Hills, Calif., USA) using the glucose hexokinase method (Boehringer Mannheim Glucose/HK Reagent Set).
Serum fructosamine. Blood samples were collected in serum separator tubes and allowed to clot for 30 min for measurements of serum fructosamine concentrations along with other blood chemistry parameters. Serum fructosamine concentrations were measured by Corning SciCor Laboratories (Indianapolis, Ind., USA) using the RoTAG colorimetric assay based upon the Baker nitroblue tetrazolium method. The upper limit of normal for this assay is 285 ~tmol/1. Serum C-peptide. Serum C-peptide concentrations were measured by Corning SciCor Laboratories using the INCStar RIA kit with a detection limit of 0.1 ng/ml. The normal range for this assay is 0.5-3.0 ng/ml.
Blood HbAlc. Whole blood samples containing EDTA were haemolysed for the HbAlc assay. HbAic levels were measured by Coming SciCor Laboratories using the BioRad Variant HPLC system with a detection limit of 3.6 %. The normal range for this assay is 4.3-6.1%.
Statistical analysis.
In order for a patient to be evaluable for the 24-h plasma glucose profile, no more than three glucose values may have been missing. An evaluable patient for the fructosamine analysis was one who had a result at both screening and after 4 weeks of study drug administration.
Two-way analysis of variance with the Hochberg Adjustment [11] for multiple comparisons was performed on continuous variables. For categorical variables, a Cochran-MantelHaenszel analysis with the Hochberg Adjustment for multiple comparisons was performed. Results that were compared to baseline after 4 weeks of study drug administration were calculated by subtracting the baseline results from the 4 week resuits. For the glucose profile analysis, results obtained on Study Day 8 were defined as baseline. For the fructosamine analysis, screening results were defined as baseline.
Results
Patient disposition. We screened 323 patients for the study, and 215 patients were randomized.
Demographic characteristics. Demographic characteristics are shown in Table 1 . There were no statistically significant differences in demographic characteristics among study drug groups.
Baseline comparability. The results of baseline comparability for 24-h mean plasma glucose, fructosamine and HbAlc are shown in Table 1 . For the 24-h plasma glucose profile at baseline, mean glucose concentrations and glucose area under the curve (AUC) ( Table 2) values for all pramlintide groups were comparable to the placebo group as were the serum fructosamine concentrations. At baseline, HbAlc levels were statistically significantly higher in the placebo group compared to the pramlintide 60 ~tg BID group but all other pramlintide groups were comparable to placebo. In addition, baseline serum C-peptide concentrations in the pramlintide 30 pg QID, 30 ~tg TID (BLD), 30 ~tg TID (BDS) and 60 ~tg BID groups (0.36 + 0.03, 0.43 + 0.05, 0.40 + 0.04 and 0.37 + 0.03 ng/ml, respectively) were not statistically significantly different from that in the placebo group (0.42 + 0.04 ng/ml).
Twenty-four hour glucose profile.
Results for the 24-h plasma glucose profile following 4 weeks of study drug administration are shown in Table 2 and Figure 1 . The mean reductions in mean glucose concentration, glucose AUC and glucose Cma x were greater with pramlintide 30 ~tg QID and 60 pg BID than with placebo; however, the mean reductions compared to placebo in mean glucose concentration reached statistical significance only with pramlintide 30 ~tg QID (p = 0.009), while the mean reduction compared to placebo in glucose Cmax with this dose regimen approached statistical significance (p = 0.082). The mean difference between the 30 ~tg QID dose of pramlintide and placebo of 1.7 mmol/1 is similar to the difference of 1.9 mmol/ 1 reported earlier from a 2-week study of pramlintide [12] .
Fasting plasma glucose concentrations were assessed as part of a meal tolerance test (not reported here) administered at baseline and after 2 and 4 weeks of randomized treatment. The five groups had mean entry fasting glucose concentrations ranging from 11.1 to 13.2 mmol/1. The mean fasting glucose concentration increased by 0.4 in the placebo group and ranged from an increase of 0.2 to a reduction of 2.2 mmol/1 in the 4 pramlintide groups after 4 weeks of randomized treatment. None of the pramlintide groups had changes that differed statistically from placebo although the reduction of 2.2 mmol/1 in the 60 ~tg BID group was statistically significant within the group (p = 0.013).
Fructosamine. Mean serum fructosamine concentrations at baseline and following 4 weeks of study drug administration are illustrated in Figure 2 . The mean serum fructosamine concentrations after 4 weeks were reduced more for all pramlintide treatment groups than with placebo, although the mean reduction in fructosamine compared to placebo reached statistical significance with the Hochberg adjustment for multiple comparisons only with pramlintide 30 ~tg QID. Compared to placebo, the mean reductions in fructosamine concentrations approached statistical significance for the pramlintide 30 ~tg TID (BDS) and 60~tg BID groups (p=0.025 and p --0.062, respectively).
The cumulative percentage distribution of the change in serum fructosamine concentrations from baseline to the end of the 4-week trial is illustrated in Figure 3 . This data display allows each subject's response to be appreciated with the results shown in rank order and allows assessment of all results as opposed to a calculated mean and standard deviation. Twenty-three percent (23 %) of patients in the pramlintide 30 ~tg QID group who had an abnormal serum ffuctosamine concentration prior to treatment had a normal serum fructosamine concentration at the end of the trial compared to 5 % of the patients in the placebo group. One patient (5%) in the 30~g QID group had a normal fructosamine concentration at baseline and an abnormal concentration at the end of the trial. Patients and investigators were allowed to adjust insulin doses based on routine home blood glucose monitoring results. Investigators continued to use their individual method for insulin adjustment as the protocol intentionally did not attempt to dictate a specific method for insulin adjustment. Investigators were requested to maintain consistent guidelines within their study subjects. These guidelines resulted in a mean increase of daily short-acting insulin by 3.6 IU in the placebo group and a mean reduction from 1.0 to 2.3 IU in each of the pramlintide treatment groups. Changes in intermediate-acting insulin doses were less consistent. As noted in Table 3 , these changes resulted in a mean increase in 24 h plasma insulin concentrations in the placebo group and a mean Fig.1 . Plasma glucose (mean + SEM) concentrations during 24 h test periods after placebo lead-in and after 4 weeks of pramlintide or placebo administration for the five study groups the most commonly reported adverse events during the trial. Although hypoglycaemia was reported with a somewhat lower incidence in the pramlintide 30 ~tg TID (BLD) group (12.2 %), the incidence of hypoglycaemia was comparable among the pramlintide 30 ~tg QID group (22.2 %), pramlintide 30 Ixg TID (BDS) group (25.0%), pramlintide 60~tg BID group (20.9%) and placebo group (26.2%). Similarly, in the subset of patients with constant insulin dose regimens, the incidence of hypoglycaemia was somewhat lower in the pramlintide 30 ~tg TID (BLD) group (14.8%) and was comparable in the pramlintide 30 ~tg QID group (27.8%), pramlintide 30 Ixg TID (BDS) group (40.0 %), pramlintide 60 ~tg BID group (25.0 %) and placebo group (31.8 %). Severe hypoglycaemia, defined as requiring the assistance of another individual was reported by 3 of the 173 subjects (1.7 %) receiving pramlintide and 1 of 42 subjects (2.4 %) receiving pramlintide.
Gastrointestinal adverse events (nausea and anorexia) occurred more frequently in the pramlintide groups (nausea, 16-37 %, anorexia, 2-9 %) than in the placebo group (nausea, 5 %, anorexia, 0 %). The highest incidence of nausea was in the pramlintide 60 mg BID group. Vomiting occurred infrequently and with a similar incidence in the pramlintide groups and the placebo group (pramlintide, 2 %, placebo 2 %). A majority of the patients who reported nausea reported it only during Week 1. Twenty seven (27) of the 41 patients in the pramlintide groups who reported nausea reported it only during Week 1.
There were a minimal number of reports of injection site events such as ecchymosis, haemorrhage, etc. with no difference between placebo and pramlintide treatment groups. Pain on injection was not reported.
Six of the 173 patients who received pramlintide (3.5 %) withdrew prematurely due to gastrointestinal adverse events. All withdrawals occurred during the initial 9 days of treatment. No patients withdrew for other adverse events. 
Discussion
This study builds upon previous reports of the effects of amylin replacement therapy using pramlintide, an analogue of human hormone, amylin, upon glycaemic control in patients with IDDM [12] . The extension of the period of treatment to 28 days allows fructosamine to be used as an assessment of glucose control. Fructosamine has been shown to reflect integrated plasma glucose concentration over the prior 14-21 days and is free of various confounding effects inherent in the use of plasma glucose assessments.
There was a statistically significant decrease in the serum fructosamine concentration compared to placebo after 4 weeks of pramlintide 30 ~tg QID Results from the other treatment regimens supported a similar trend but did not achieve statistical significance. There were statistically significant and clinically important decreases in the mean glucose concentration and in the 24-h plasma glucose profile compared to placebo following 4 weeks of pramlintide 30 ~tg QID administration. Results from the other treatment regimens supported a similar trend but were not statistically significant.
The results observed in this study were associated with mean peak pramlintide concentrations following the initial injection on the final day of the study ranging from 22.8 to 24.4 pmol/1 for the groups receiving 30 ~tg doses and was 39.7 pmol/l in the subjects receiving the 60 ~tg dose. This compares to published results of endogenous amylin non-glycosylated amylin concentrations increasing to 13.6 + 1.9 pmol/1 and total amylin concentrations increasing to 26,2 + 2.7 pmol/1 after Sustacal in healthy subjects [13] .
Alterations in insulin dosing regimens can impact on plasma glucose control. Although the mean differences in total daily insulin administered at baseline and week 4 were relatively small in each of the study ~ groups, alterations in insulin dosing regimens were documented in a number of individual patients during this study. Specifically, during the study 28 patients changed their total daily insulin dose by more than 10 % and 34 patients changed their number of insulin injections. The changes in 24 h insulin concentrations as shown in Table 4 indicate that the insulin changes made during this study would minimize the independent effect of pramlintide to improve glucose control and fructosamine results. Because this study was blinded and each investigator used similar treatment goals for each patient, the increase in 24 h insulin concentrations in the placebo group compared to the decrease in 24 h insulin concentrations in each pramlintide group provides additional indirect evidence of the biological activity of pramlintide on glucose control.
As in previous studies [10, 12] , nausea occurred more frequently in patients in the pramlintide groups than in the placebo group. However, nausea was a transient event that subsided after the first week of pramlintide administration in most patients. Although nausea was mild in most patients, 3.5 % of patients receiving pramlintide experienced nausea of sufficient severity to prompt their withdrawal from the study.
The nausea did not result in significant dietary changes based on patient history. Specifically, either 3 or 4 subjects (7.1 to 9.8 %) reported a change in diet in each of the pramlintide treatment groups compared to 4 (9.8 %) in the placebo group. Weight changes in this 4-week study were not clinically important. Two of the four pramlintide groups had a mean reduction of 0.7 and 0.9 kg while the placebo group had a mean increase of 0.2 and the other pramlintide groups had mean increases of 0.03 and 0.2 kg. Longer studies are underway that will allow more accurate assessment of the effect of pramlintide on weight.
Most patients reported at least one hypoglycaemic event during pramlintide or placebo administration, although there were no differences in the incidence of hypoglycaemic events between the four pramlintide groups. Data on hypoglycaemia were collected at each visit as part of the history. Severe events, defined as an event that needed the assistance of another individual were tracked separately in addition to the milder events. The incidence of hypoglycaemia was no greater in any pramlintide group than in the placebo group, either in all evaluable patients or in the subset of patients with a constant insulin dose regimen. Therefore, improved blood glucose control was achieved by pramlintide without a reported increase in either severe of self-reported hypoglycaemia. As expected the incidence of hypoglycaemia increased just prior to meal time in the placebo group while the timing of hypoglycaemia in the pramlintide treatment groups was less predictable.
The Diabetes Control and Complications Trial demonstrated the effectiveness of intensive therapy with insulin in delaying the development and progression of diabetic retinopathy, nephropathy and neuropathy in patients with IDDM [14] . However, in that trial, intensive therapy with insulin was associated with an approximately threefold increase in the incidence of severe hypoglycaemia [15] . Difficulties associated with intensive insulin therapy, particularly the increase in severe hypoglycaemia, have focused attention on the need for therapeutic approaches that improve glucose control without increasing the risk for hypoglycaemia. This study showed no increase in the incidence of hypoglycaemia despite the improved glucose control in the pramlintide groups as compared to placebo.
Current evidence suggests that the mechanism of action of pramlintide is complementary to the. action of insulin. Amylin has been shown to modulate the rate of gastric emptying in both rats [7] and dogs [6] . Similar effects of pramlintide have been demonstrated in man [16] . In addition, amylin has been shown to suppress arginine-induced glucagon secretion in rats [5] . The addition of pramlintide to the treatment regimen of insulin-treated patients appears to assist in improving glucose control, at least in part, by slowing the rate of nutrient absorption from the intestinal tract and thereby lowering postprandial glucose concentrations. Since this delayed delivery results in delayed initial absorption, it may prove easier to match the arrival of glucose into the bloodstream with the time course of action of the administrated insulin. In addition, the period of glucose absorption is likely prolonged, an effect that provides a potential buffer against hypoglycaemia.
Delaying gastric emptying raises potential concerns related to gastroparesis. While gastroparesis occurs as a late-stage complication of diabetes, the incidence with which it occurs is poorly documented [17] . Recent reports strongly suggest that a significant number patients with both IDDM and NIDDM actually have accelerated rates of gastric emptying [18, 19] . While gastric emptying rates were not assessed in this study, no clinical evidence emerged to suggest that excessive delays in gastric emptying were occurring in pramlintide treated patients.
In summary, 4 weeks of pramlintide administration significantly reduced both serum fructosamine and 24-h plasma glucose concentrations in patients with IDDM. The 30 ~tg QID dosing regimen was active and the results from the TID and BID dosing regimens suggest that less frequent dosing may also be active in some patients. The incidence of hypoglycaemic events was no greater in any pramlintide group than in the placebo group, indicating an improvement in glucose control without an increase in hypoglycaemia. Therefore, future studies involving longer treatment periods with assessment of HbAlc as the measurement of glycaemic control are warranted in order to better understand the potential benefits that pramlintide may add to the diabetes treatment.
